Bone Health Considerations in Breast Cancer.
Kristen L Fessele
PMID 35477651WHAT IT FOUND
Breast cancer endocrine therapy can rapidly reduce bone density.
Use bone density screening, calcium, vitamin D, weight-bearing exercise, and consider bisphosphonates when fracture risk warrants.
Key findings
01Endocrine therapy can cause rapid bone loss, with clinically significant bone mineral density changes as early as 6 months from treatment initiation.
02Patients with non-metastatic disease receiving therapy that increases bone loss risk should undergo bone density screening every 2 years, and more frequently if decline is severe or fast.
03Resistance and impact activities at least twice weekly that generate 3 to 4 times body weight appear most effective to slow hip and spine bone loss.
STILL TO COME
How it was doneWhat they foundWhat it means for PTsWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
This is a review, not a trial, so it does not provide new patient-level evidence. The supplied text does not include the tables that define osteoporosis categories, calcium recommendations, or vitamin D recommendations. The paper cites guidelines and prior studies, but the full methods of those sources are not available here. Some recommendations are conditional, and the paper says ovarian suppression data remain equivocal for low-risk patients.
Declared interests
The supplied text does not include an author conflict-of-interest declaration. The article is listed as receiving extramural N.I.H. research support.
The easy way to misread this
Do not treat this as a single study that shows exercise or bisphosphonates will prevent fractures for every patient. It is a review of guidelines and prior evidence, and treatment choices depend on cancer stage, therapy, fracture risk, and contraindications.